AE Wealth Management’s SAB Biotherapeutics SABS Stock Holding History

AE Wealth Management’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,870	Closed	-$11K	–	1990
2022 Q4	$11K	Hold	1,870	–	–	﹤0.01%	1796
2022 Q3	$13K	Hold	1,870	–	–	﹤0.01%	1722
2022 Q2	$27K	Hold	1,870	–	–	﹤0.01%	1694
2022 Q1	$70K	Buy	+1,870	New	+$86.3K	﹤0.01%	1625

Other funds holding SABS

FPB

First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

IFAM

Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

AE Wealth Management's SABS Position: Q1 2023 in Review

AE Wealth Management sold out of SAB Biotherapeutics (SABS) in Q1 2023, closing a stake of 1,870 shares — an estimated $11K sold.

AE Wealth Management first reported a position in SABS in Q1 2022 and held it in 4 quarters. The position peaked at $70K in Q1 2022. 39 funds tracked by Wall St. Rank hold SABS as of Q1 2023.

AE Wealth Management reported no remaining SAB Biotherapeutics position as of Q1 2023 after selling out during the quarter.
AE Wealth Management sold 1,870 SAB Biotherapeutics shares in Q1 2023, an estimated $11K.
AE Wealth Management first reported a position in SAB Biotherapeutics in Q1 2022 and held it in 4 quarters.
AE Wealth Management's SAB Biotherapeutics position peaked at $70K in Q1 2022.
39 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2023.

Based on AE Wealth Management's 13F filing for Q1 2023, filed 14 Apr 2023.